Additional Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia

被引：0

作者：

Satlin, Andrew ^{[1
]}

Vanover, Kimberly ^{[1
]}

Durgam, Suresh ^{[1
]}

Mates, Sharon ^{[1
]}

Davis, Robert ^{[1
]}

Correll, Christoph ^{[1
]}

机构：

[1] Intracellular Therapies Inc, New York, NY USA

来源：

NEUROPSYCHOPHARMACOLOGY | 2019年 / 44卷 / SUPPL 1期

关键词：

Schizophrenia; Antipsychotics; Open Label Trials; Clinical Trial; Long-Term Safety;

D O I：

暂无

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

W203

引用

页码：493 / 494

页数：2

共 50 条

[1] Results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia
Correll, C. U.
Vanover, K. E.
Durgam, S.
Weingart, M.
Davis, R.
Satlin, A.
[J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S455 - S456
[2] LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
Vanover, Kimberly
Dmitrienko, Alex
Glass, Steven
Kozauer, Susan
Saillard, Jelena
Weingart, Michal
Satlin, Andrew
Mates, Sharon
Correll, Christoph
Davis, Robert
[J]. SCHIZOPHRENIA BULLETIN, 2018, 44 : S341 - S341
[3] FAVORABLE LONG-TERM SAFETY PROFILE OF LUMATEPERONE IITI-007): RESULTS FROM A 12 MONTH OPEN LABEL SAFETY STUDY FOR LUMATEPERONE IN PATIENTS WITH STABLE SYMPTOMS OF SCHIZOPHRENIA
Vanover, Kimberly
Satlin, Andrew
Durgam, Saresh
Weingart, Michal
Saillard, Jelena
Sanchez, Juan
Hossain, Shawon
Glass, Steven
Kozauer, Susan
Mates, Sharon
Davis, Robert
[J]. SCHIZOPHRENIA BULLETIN, 2019, 45 : S351 - S351
[4] LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
Davis, Robert
Dmitrienko, Alex
Glass, Steven
Kozauer, Susan
Saillard, Jelena
Weingart, Michal
Satlin, Andrew
Mates, Sharon
Correll, Christoph
Vanover, Kimberly
[J]. SCHIZOPHRENIA BULLETIN, 2018, 44 : S236 - S237
[5] Cardiometabolic safety of lumateperone (ITI-007): post hoc analyses of short-term randomized trials and an open-label long-term study
Satlin, A.
Durgam, S.
Vanover, K. E.
Davis, R. E.
Chen, R.
Mates, S.
Correll, C. U.
[J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S265 - S266
[6] Favorable Clinical Safety Profile for Lumateperone (ITI-007) - Switching From Standard-Of-Care Antipsychotic Therapy in Patients With Schizophrenia
Vanover, Kimberly
O'Gorman, Cedric
Glass, Steven
Saillard, Jelena
Weingart, Michal
Mates, Sharon
Correll, Christoph
Davis, Robert
[J]. NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S416 - S417
[7] Lumateperone 42 mg in an Open-Label Switch Study in Patients with Stable Schizophrenia: Results by Previous Antipsychotic
Cutler, Andrew J.
Edwards, John B.
Durgam, Suresh
Mo, Yifan
Acosta, Jazmin
Davis, Robert E.
[J]. CNS SPECTRUMS, 2023, 28 (02) : 235 - 236
[8] Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
Kimberly E. Vanover
Robert E. Davis
Yun Zhou
Weiguo Ye
James R. Brašić
Lorena Gapasin
Jelena Saillard
Michal Weingart
Robert E. Litman
Sharon Mates
Dean F. Wong
[J]. Neuropsychopharmacology, 2019, 44 : 598 - 605
[9] Safety and tolerability profile of lumateperone (ITI-007): Results from a phase 3 clinical trial for the treatment of bipolar depression
Yatham, Lakshmi
Durgam, Suresh
Satlin, Andrew
Vanover, Kimberly E.
Davis, Robert E.
Kozauer, Susan G.
Huo, Jason
Mates, Sharon
[J]. BIPOLAR DISORDERS, 2020, 22 : 83 - 83
[10] Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
Vanover, Kimberly E.
Davis, Robert E.
Zhou, Yun
Ye, Weiguo
Brasic, James R.
Gapasin, Lorena
Saillard, Jelena
Weingart, Michal
Litman, Robert E.
Mates, Sharon
Wong, Dean F.
[J]. NEUROPSYCHOPHARMACOLOGY, 2019, 44 (03) : 598 - 605

← 1 2 3 4 5 →